ArticleInternational wound journal2024
Improving properties of platelet-rich fibrin scaffold with tannic acid for wound healing.
Article in International wound journal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 13 citations in OpenAlex.
- Use of Platelet-Rich Fibrin and Platelet-Rich Plasma as Delivery Systems for Natural Compounds: A Systematic Review.Materials (Basel, Switzerland) · 2026Review
- Tannic acid modified horizontal platelet-rich fibrin membrane with improved mechanical and biological properties for tissue regeneration : Author full names.Scientific reports · 2025Article
- Platelet-Rich Fibrin Synthetic Bone Graft Enhances Bone Regeneration and Mechanical Strength in Rabbit Femoral Defects: Micro-CT and Biomechanical Study.Journal of functional biomaterials · 2025Article
- Plasma-rich fibrin gel and adipose-derived allogeneic mesenchymal stem cells: innovation in the treatment of second-degree deep burn wound; characterization and in-vivo study.Cell and tissue banking · 2025Article
- Deconstructing fibrin(ogen) structure.Journal of thrombosis and haemostasis : JTH · 2025Review
- Developing fibrin-based biomaterials/scaffolds in tissue engineering.Bioactive materials · 2024Review
- Improving properties of platelet-rich fibrin scaffold with tannic acid for wound healing.International wound journal · 2024Article
- Navigating the combinations of platelet-rich fibrin with biomaterials used in maxillofacial surgery.Frontiers in bioengineering and biotechnology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Platelet-rich fibrin (PRF), which is the rich source of growth factors, has been used as an efficient scaffold in tissue engineering and wound healing. In this study, tannic acid as a green cross-linker with different concentrations (0.5%, 1%, 5% and 10%) was used to improve the properties of PRF. The cross-linked gel scaffolds were evaluated by analyses such as scanning electron microscopy, Fourier transform infrared spectroscopy, swelling and degradation, mechanical strength, cell toxicity, cell adhesion and antibacterial test. The results showed that the scaffold structure changes by increasing cross-linker concentration. The swelling rate decreased from 49% to 5% for the samples without the cross-linker and with tannic acid (10%), respectively. The degradation percentage for the cross-linked samples was 8%, which showed a lower degradation rate than the non-cross-linked samples (63%). The mechanical strength of the scaffold with the cross-linker increased up to three times (Young's modulus for the non-cross linked and the cross-linked samples: 0.01 and 0.6 MPa, respectively). Cytotoxicity was not observed up to 10% cross-linker concentration. The cells proliferated well on the cross-linked scaffolds and also showed a good antibacterial effect. In general, tannic acid can improve the physical and mechanical properties of PRF without negatively affecting its biological properties.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.